NASDAQ: DYNDyne Therapeutics Inc Stock
$13.72+0.03 (+0.22%)
Updated Jan 24, 2025
DYN Price
$13.72
Fair Value Price
$1.58
Market Cap
$1.40B
52 Week Low
$13.45
52 Week High
$47.45
P/E
-3.85x
P/B
1.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$294.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$243M
Beta
1.45
Next Earnings
Mar 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DYN Overview
Dyne Therapeutics, Inc. is a biotechnology company focusing treatments for genetically driven muscle diseases in the U.S. Its products and programs target myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases. Dyne Therapeutics was incorporated in 2017 and is headquartered in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DYN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Value
D
Growth
D
Momentum
D
Sentiment
C
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DYN
Ranked#528 of 555
Ranked#528 of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important DYN news, forecast changes, insider trades & much more!
DYN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DYN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DYN ($13.72) is overvalued by 769.18% relative to our estimate of its Fair Value price of $1.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DYN ($13.72) is not significantly undervalued (769.18%) relative to our estimate of its Fair Value price of $1.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DYN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DYN due diligence checks available for Premium users.
Valuation
DYN fair value
Fair Value of DYN stock based on Discounted Cash Flow (DCF)
Price
$13.72
Fair Value
$1.58
Overvalued by
769.18%
DYN ($13.72) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DYN ($13.72) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DYN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DYN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.85x
Industry
-188.16x
Market
30.33x
DYN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.98x
Industry
5.04x
DYN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DYN's financial health
Profit margin
Revenue
$0.0
Net Income
-$97.1M
Profit Margin
0%
DYN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$768.8M
Liabilities
$63.3M
Debt to equity
0.09
DYN's short-term assets ($736.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DYN's short-term assets ($736.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DYN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$74.6M
Investing
-$19.4M
Financing
$18.0M
DYN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DYN vs Biotech Stocks
Dyne Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.